00:44 , Aug 10, 2019 |  BC Extra  |  Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:49 , Jun 6, 2019 |  BC Extra  |  Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
19:42 , May 2, 2019 |  BC Extra  |  Financial News

May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

Magenta follow-on comes with haircut  Stem cell transplant company Magenta Therapeutics Inc. (NASDAQ:MGTA) raised $56.3 million in a follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow. At $13.25 per share, the price...
21:58 , Apr 26, 2019 |  BioCentury  |  Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
00:27 , Apr 13, 2019 |  BioCentury  |  Tools & Techniques

ctDNA inches toward new applications

After establishing itself as a key tool for tumor profiling and patient stratification, circulating tumor DNA is now beginning to make the move into monitoring response to therapy, where it promises an early read of...
23:17 , Apr 12, 2019 |  BC Extra  |  Clinical News

Clovis down after discontinuing rucaparib bladder cancer trial

Clovis was off $3.08 (13%) to $20.40 in after-hours trading Friday after the company disclosed that it discontinued the Phase II ATLAS trial of Rubraca rucaparib as monotherapy to treat locally advanced unresectable or metastatic...
20:25 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer

Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...